Huaren Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2020: 0.10%

Huaren Pharmaceutical Co Ltd (300110) has an Asset Resilience Ratio of 0.10% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥3.00 Million
≈ $438.99K USD Cash + Short-term Investments

Total Assets

CN¥2.87 Billion
≈ $420.66 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2019)

This chart shows how Huaren Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check Huaren Pharmaceutical Co Ltd (300110) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Huaren Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300110 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥3.00 Million 0.1%
Total Liquid Assets CN¥3.00 Million 0.10%

Asset Resilience Insights

  • Limited Liquidity: Huaren Pharmaceutical Co Ltd maintains only 0.10% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Huaren Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Huaren Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
Drug Manufacturers - Specialty & Generic 2.04%
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
Drug Manufacturers - Specialty & Generic 0.01%
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
Drug Manufacturers - Specialty & Generic 7.85%
Jw Pharmac
KO:001060
Drug Manufacturers - Specialty & Generic 3.65%
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Samjin Pharm
KO:005500
Drug Manufacturers - Specialty & Generic 0.25%

Annual Asset Resilience Ratio for Huaren Pharmaceutical Co Ltd (2017–2019)

The table below shows the annual Asset Resilience Ratio data for Huaren Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2019-12-31 0.11% CN¥2.85 Million
≈ $417.04K
CN¥2.71 Billion
≈ $396.60 Million
-0.28pp
2017-12-31 0.38% CN¥11.11 Million
≈ $1.63 Million
CN¥2.89 Billion
≈ $422.47 Million
--
pp = percentage points

About Huaren Pharmaceutical Co Ltd

SHE:300110 China Drug Manufacturers - Specialty & Generic
Market Cap
$470.55 Million
CN¥3.22 Billion CNY
Market Cap Rank
#12403 Global
#3579 in China
Share Price
CN¥2.72
Change (1 day)
+1.49%
52-Week Range
CN¥2.47 - CN¥3.63
All Time High
CN¥13.46
About

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more